DCF Advisers’s Biogen BIIB Stock Holding History

DCF Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$232K	–	99
2024 Q2	$232K	Buy	+1,000	New	+$217K	0.12%	83
2023 Q2	–	Sell	-4,900	Closed	-$1.36M	–	90
2023 Q1	$1.36M	Buy	+4,900	New	+$1.36M	0.83%	30
2021 Q4	–	Sell	-2,000	Closed	-$566K	–	77
2021 Q3	$566K	Buy	2,000 +1,000	+100%	+$328K	0.25%	61
2021 Q2	$346K	Buy	+1,000	New	+$303K	0.12%	78

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCF Advisers's BIIB Position: Q3 2024 in Review

DCF Advisers sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,000 shares — an estimated $232K sold.

DCF Advisers first reported a position in BIIB in Q2 2021 and held it in 4 quarters. The position peaked at $1.36M in Q1 2023. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

DCF Advisers reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
DCF Advisers sold 1,000 Biogen shares in Q3 2024, an estimated $232K.
DCF Advisers first reported a position in Biogen in Q2 2021 and held it in 4 quarters.
DCF Advisers's Biogen position peaked at $1.36M in Q1 2023.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.